ONM-501
Advanced solid tumors and lymphomas
Phase 1Active
Key Facts
About OncoNano Medicine
OncoNano Medicine is a private, clinical-stage biotech leveraging its ON-BOARD™ polymeric micelle platform to develop targeted cancer therapies. The platform exploits the universal hallmark of tumor acidity to improve drug delivery, aiming to enhance therapeutic efficacy while minimizing systemic toxicity. The company's most advanced program, ONM-501, is in Phase 1 trials, and OncoNano is actively seeking partnerships to expand the application of its delivery technology. With a seasoned leadership team and a research collaboration with Gilead, the company is positioned to advance its pipeline of novel oncology treatments.
View full company profile